BioInvent International AB Sustainability Reports
BioInvent International AB is a clinical-stage biotechnology company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer immunotherapies. The company leverages its proprietary F.I.R.S.T technology platform and n-CoDeR antibody library to advance its clinical programs and manage in-house GMP manufacturing.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300E7QRHEF2IJUY10
FIGI: BBG001SBWR52
22 reports from 2007 to 2026